Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
N-acetylcysteine and antithrombin III for ischemia-reperfusion injury reduction after simultaneous pancreas-kidney transplantation
2007-003728-39Phase 3Completed
- Sponsor
- Centre Hospitalier Universitaire de Liège
- Start
- May 2010
- Modality
- Small Molecules, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of antithrombin III concentrate and acetylcysteine in ischemia-reperfusion injury (IRI) (3 arms), sponsored by Centre Hospitalier Universitaire de Liège. Primary endpoint: Pancreas graft reperfusion pancreatitis. Started May 2010; status: completed.
02
Drugs
antithrombin III concentrateacetylcysteine
03
Conditions
ischemia-reperfusion injury (IRI)
Beyond the preview
Go deeper on 2007-003728-39.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-003728-39.